Pre-validation of a MALDI MS proteomics-based method for the reliable detection of blood and blood provenance by Kennedy, Katie et al.
Pre-validation of a MALDI MS proteomics-based method 
for the reliable detection of blood and blood provenance
KENNEDY, Katie, HEATON, Cameron, LANGENBURG, Glenn, COLE, Laura, 
CLARK, Tom, CLENCH, Malcolm R., SEARS, Vaughn, SEALEY, Mark, 
MCCOLM, Richard and FRANCESE, Simona <http://orcid.org/0000-0002-
1381-1262>
Available from Sheffield Hallam University Research Archive (SHURA) at:
http://shura.shu.ac.uk/27395/
This document is the author deposited version.  You are advised to consult the 
publisher's version if you wish to cite from it.
Published version
KENNEDY, Katie, HEATON, Cameron, LANGENBURG, Glenn, COLE, Laura, 
CLARK, Tom, CLENCH, Malcolm R., SEARS, Vaughn, SEALEY, Mark, MCCOLM, 
Richard and FRANCESE, Simona (2020). Pre-validation of a MALDI MS proteomics-
based method for the reliable detection of blood and blood provenance. Scientific 
Reports, 10 (1), p. 17087. 
Copyright and re-use policy
See http://shura.shu.ac.uk/information.html
Sheffield Hallam University Research Archive
http://shura.shu.ac.uk
1Vol.:(0123456789)
Scientific Reports |        (2020) 10:17087  | https://doi.org/10.1038/s41598-020-74253-z
www.nature.com/scientificreports
Pre‑validation of a MALDI MS 
proteomics‑based method 
for the reliable detection of blood 
and blood provenance
Katie Kennedy1,6, Cameron Heaton1,6, Glenn Langenburg2, Laura Cole1, Tom Clark3, 
Malcolm R. Clench1, Vaughn Sears4, Mark Sealey5, Richard McColm5 & Simona Francese1*
The reliable identification of blood, as well as the determination of its origin (human or animal) is of 
great importance in a forensic investigation. Whilst presumptive tests are rapid and deployed in situ, 
their very nature requires confirmatory tests to be performed remotely. However, only serological 
tests can determine blood provenance. The present study improves on a previously devised Matrix 
Assisted Laser Desorption Ionisation Mass Spectrometry (MALDI MS)—proteomics based method 
for the reliable detection of blood by enabling the determination of blood provenance. The overall 
protocol was developed to be more specific than presumptive tests and faster/easier than the gold 
standard liquid chromatography (LC) MS/MS analysis. This is considered a pre‑validation study that 
has investigated stains and fingermarks made in blood, other biofluids and substances that can elicit 
a false‑positive response to colorimetric or presumptive tests, in a blind fashion. Stains and marks 
were either untreated or enhanced with a range of presumptive tests. Human and animal blood 
were correctly discriminated from other biofluids and non‑biofluid related matrices; animal species 
determination was also possible within the system investigated. The procedure is compatible with 
the prior application of presumptive tests. The refined strategy resulting from iterative improvements 
through a trial and error study of 56 samples was applied to a final set of 13 blind samples. This final 
study yielded 12/13 correct identifications with the 13th sample being correctly identified as animal 
blood but with no species attribution. This body of work will contribute towards the validation of 
MALDI MS based methods and deployment in violent crimes involving bloodshed.
The reliable detection of bloodstains at the scene of violent crimes is of crucial importance to both reconstruct 
the dynamics of the crime and to provide, if present, associative evidence. Particularly the presence of blood in 
fingermarks yields such associative evidence.
Crime scene investigators and forensic laboratories employ a range of blood enhancement techniques (BET) 
applicable to either stains or fingermarks. As previously  reported1,2, these methods may be prone to false posi-
tives (and are therefore considered presumptive). This is due to the relatively unspecific nature of their molecular 
targets.
The most commonly known false positive example is the reaction of luminol (haem reactive test) to bleach. 
A less reported example is represented by the false positive reaction of acid dyes to biofluids other than blood, 
such as semen and saliva. In this respect, the lack of specificity in the identification of blood is worsened by 
the risk of not detecting other types of biofluids which are important indicators of the crime being committed. 
The detection of other biofluids would permit a comprehensive reconstruction of the events. For example, in a 
homicide crime scene, the presence of semen on the victim, or around a body may indicate that some level of 
sexual activity has also occurred (from consensual intercourse to rape).
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Other important aspects to consider are sequential workflows to gather a body of intelligence from a single 
evidential source. Blood tests such as the presumptive haem specific Luminol, BlueStar and confirmatory tests 
such as the Takayama Test, have been shown to result in DNA degradation at 30 days post application; this may 
be an issue for cases when further DNA analysis is  required3 but the analysis is not conducted immediately after 
collection. DNA provides a profile of the individual to whom the blood belongs to (if blood is present). It can 
relay extremely valuable information to both an investigation and judicial debates but does not provide informa-
tion on the nature of the biofluid that it may be found within. As such, even if the identity of the perpetrator can 
be retrieved, the detection of blood may be missed and thus, valuable information may still be lacking around 
the nature and dynamics of the crime. Due to the limitations of the presumptive tests and DNA techniques, 
it becomes very important to have validated techniques characterised by high specificity in the detection of 
blood (and better still of other biofluids also) that, ideally, do not interfere with the subsequent process of DNA 
sampling and analysis.
Deininger et al. reviewed spectroscopic techniques for blood detection including Raman and hyperspectral 
imaging (HSI)2. Despite these techniques showing great promise for blood detection and distribution mapping, 
they are not be suitable when blood is recovered from red and dark substrates. Furthermore the need to acquire 
a reference spectrum at a crime scene without any blood would be challenging, as blood contaminated stains or 
fingermarks can often be latent at crime scenes.
Mass spectrometry (in different forms) has the advantage of being much more specific compared to spec-
troscopic methods as it detects the compound of interest by measuring the specific mass-to-charge (m/z) ratio; 
the compound identity can also be confirmed by tandem mass spectrometry experiments. The gold standard for 
detecting protein biomarkers such as those specific to blood is still currently mass spectrometry-based proteomics 
through liquid chromatography (LC) hyphenated with Tandem mass spectrometry (LC MS/MS). This is due to 
both the superior number of protein species detected and the confirmatory value of MS/MS experiments (which 
can be conducted on single and multiply charged ions). Iliano et al.4 reported on the use of LC MS/MS to dis-
criminate different biofluids, by identifying several semen, saliva and blood specific markers. In particular, blood 
specific proteins detected in the samples analysed included haemoglobin (HB), hemopexin and haptoglobin.
However, LC MS/MS remains rather time consuming from both a sample preparation point of view and data 
acquisition. In biomarker discovery studies, the benefits outweigh the downsides, due to the necessity to map 
the entire proteome and much more relaxed time constraints.
Nonetheless, one should carefully evaluate the analytical context and the type of information sought for the 
selection of the analytical technique to be used. In the context of forensic identification of blood and biofluids, a 
technique that yields only a handful of blood/biofluid biomarkers, but that is faster and more user friendly, may 
potentially be more suitable than LC MS/MS.
MALDI MS could represent one such alternative technique. This hypothesis is supported by the work of Yang 
et al.5 in 2013 who devised a MALDI MS and MS/MS method for the differentiation of blood and other bod-
ily fluids. However the method also included prior chromatographic separation, making the whole procedure 
possibly even more laborious. Jiang et al. uniquely used MALDI FT ICR MS followed by multivariate statistical 
analysis to differentiate blood and other  biofluids6. In the study by Kamanna et al.7 published in 2017, MALDI 
MS was employed to detect blood and vaginal fluid biomarkers with or without enhancement using a BET. 
Blood was confirmed by the presence of haem and HB most abundant peptides (as well as intact HB analysis). 
Bradshaw et al.8 demonstrated in 2014 that MALDI MS Imaging (MALDI MSI) was successful in detecting intact 
haem and HB visualising them in blood marks with and without prior enhancement. Patel et al. and Deininger 
et al.2,9 further investigated blood detection in human blood stains and blood fingermarks using a MALDI MS 
and MALDI MSI based proteomic approach. Within both of these studies, the most abundant and specific blood 
proteins such as haemoglobin α (αHB) and β (βHB), hemopexin, serotransferrin, complement C3, alpha-1 anti-
trypsin, apolipoprotein A1, alpha-2-macroglobulin, erythrocyte membrane protein band (EPB) 3 and 4.2 were 
detected, with many of these proteins being highly specific to blood and with EPB 3 being specifically found in 
the human red blood cell membranes.
The inclusion of multiple blood-specific proteins is a more specific approach compared to those previously 
described as, although HB is specific to blood, it may be found as a trace contaminant in other biofluids. Fur-
thermore, Bradshaw et al.8 Patel et al.9 and Kamanna et al.10 demonstrated the possibility to determine blood 
provenance which can be valuable in an investigation.
Taken together these studies indicate MALDI MS Profiling (MALDI MSP) and MALDI MS Imaging (MALDI 
MSI) based proteomic approaches as a viable and quicker alternative to LC MS/MS methods and as confirma-
tory tests for both blood detection and provenance. However, despite the potential that MALDI MS has shown 
for its operational use in blood detection and provenance, no method validation has been conducted, hence the 
operational implementation both for live and cold cases is somewhat hindered.
In the present study, the authors report on a “pre-validation” study where the methods developed by Patel et al. 
and Deininger et al.2,9 (in which the reduction and alkylation step were removed) are improved and applied to a 
variety of stains and fingermarks. These samples were deposited on aluminium slides and included blood, other 
biofluids (human semen, saliva and sweat) and non-biofluids related matrices (ketchup, egg, yolk, body lotion, 
steak sauce, beetroot juice). All samples were prepared unenhanced or enhanced using three BET namely Acid 
Yellow-7 (AY-7), Leucocrystal Violet (LCV) and Acid Black 1 (AB-1).
With respect to blood samples, these were either human or animal (porcine (both domesticated and wild 
boar), bovine and chicken) and in the case of human samples, some contained Ethylenediaminetetraacetic Acid 
(EDTA) as an example of anti-coagulant. Crucially, all of the samples were prepared blind to the analysts in order 
to validate the overall method whilst eliminating any possible interpretative bias. The identity of the individual 
samples was only disclosed once the data were processed and the analyst made the “identity claim”.
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An iterative process has been used to “learn” the most efficient way to process the data for the subsequent 
determination of the nature of the sample “at glance” in a final set of 13 pre-validation samples. Whilst MS/MS has 
been undertaken to facilitate strategy development, the 13 final pre-validation samples were correctly identified 
for the presence of human and animal blood, as well as for the presence of semen, without performing MS/MS 
experiments, thus enabling a quick screening method. This pre-validation work has advised and informed on the 
best approach for further refinement and optimisation of the study design and methods so that full validation 
of this MALDI-based approach will be feasible in the near future.
Materials and methods
All experimental protocols were approved by Sheffield Hallam University (HWB-BRERG23-13-14 and 
ER13034924) and performed in accordance with relevant guidelines and regulations. An informed consent was 
obtained from the donor of the human samples prior to sample donation.
Materials. Trifluoroacetic acid (TFA), α-cyano-4-hydroxycinnamic acid (α-CHCA) and Millipore ZipTips 
containing C18 stationary phase and TLC sheets were purchased from Sigma Aldrich (Poole, UK). Acetonitrile 
(ACN) and formic acid were purchased from Fisher Scientific (Loughborough, UK). Sequencing grade modi-
fied lyophilized Trypsin was obtained from Promega in 20 µg vials (Southampton, UK). Sigma dry tubed swabs 
were sourced from Medical Wire (MWE) (Wiltshire, UK) and RapiGest was obtained in 1 mg vials from Waters 
(Wilmslow, UK). Intravenous blood samples (bovine, chicken and porcine, 1 mL defibrinated and 1 mL with 
EDTA for each animal) were purchased from TCS Biosciences (Buckingham, UK). All blind stain and finger-
mark samples were donated by Elite Forensic Services (Minnesota, USA) and used under the Ethics Applications 
(HWB-BRERG23-13-14 and ER13034924) granted by Sheffield Hallam University. Samples included human 
and animal blood (bovine, porcine, chicken, and wild boar) human biofluids (semen, saliva and sweat), non-
blood/biofluid related matrices (beetroot juice, ketchup, egg white, steak sauce). Human blood, biofluids and fin-
germarks were donated by 1 male donor at one collection time. Samples were presented both as non-enhanced 
and enhanced using blood enhancement techniques such as Acid Yellow 7, Acid Black 1 and Leucocrystal Violet 
and were prepared on TLC aluminium slides. They were subsequently packaged in glass slide containers, kept 
at room temperature prior to shipping via priority mail to the research group at Sheffield Hallam University.
Instruments and instrumental conditions. All mass spectrometric analyses were carried out using a 
Waters MALDI-QTOF Synapt G2 Si instrument (Waters Corporation, Manchester, UK). Data acquisition was 
performed within the m/z range 600–2000 Th in positive reflectron mode. The MALDI QTOF G2 Si instrument 
is supplied with a repetition rate Nd: YAG laser which was set to 1 kHz for these experiments. A 0.5 µL spot of 
saturated phosphorus red solution in ACN was used as the internal calibrant in the m/z range 600–2500 Th for 
each sample by acquiring a spectrum in the same acquisition instance as the sample. MALDI MS/MS spectra 
were obtained using argon as the collision gas; the trap collision energy was set at 100, laser power 300 and low 
mass resolution at 14.6.
LC MS/MS analyses were performed on a Xevo G2-XS QTOF (Waters Corp, Manchester, UK) equipped 
with an Acquity UPLC system (Waters Corp, Manchester, UK). For UPLC analysis, the injection volume was 5 
µL; mobile phase A consisted of 0.1% formic acid in deionised water and mobile phase B of 0.1% formic acid in 
Acetonitrile (HPLC grade). Samples were run on an Acquity Ultra Performance Liquid Chromatography (UPLC) 
HSS T3 100 Å, 1.8 µm, 2.1 × 100 mm column at a flow rate of 0.2 mL/min starting with 3% B. The mobile phase 
went from 3% B to 95% B in 49 min and ramped to 98% B in the subsequent minute and was kept constant for 
2 min. The mobile phase returned to 3% B in 4 min for an overall run duration of 56 min. Column temperature 
was set to 45 °C. MS/MS analyses were conducted in data dependent scan mode within a m/z range 100–1800 
Th. The cone voltage was set to 40 V and Collision voltage was set to 30 V for all samples.
Data processing. UniProt (https ://www.unipr ot.org/) was used to search for protein sequences of interest. 
In silico proteolysis with trypsin was performed by using the tool “peptide mass”. In silico peptide lists were 
generated by selecting “monoisotopic”, “MH+”, “2 missed cleavages” and “variable methionine oxidation” in the 
m/z range 600–2000 Th. Microsoft Excel tables were generated reporting the theoretical m/z and the sequence 
of peptides generated from (amongst other) haemoglobin (HB, α and β chains), erythrocyte membrane pro-
tein band 4, haptoglobin (Hpt), apolipoprotein, myoglobin, glycophorin A and albumin. Theoretical m/z values 
for the above peptides were reported for both human and the animal species investigated. Macros were gen-
erated to rapidly highlight proteotypic peptides present in the spectral peak list and those peptides identical 
in sequence, shared amongst the multiple species under investigation. Blood proteins were investigated from 
human, chicken, porcine, bovine and wild boar. UniProt does not make clear whether sus scrofa as taxonomy 
refers to the wild boar or domestic pig. Proteins from both these animals were all identified as deriving from sus 
scrofa, therefore a distinction between domestic pig and wild boar could not be made. Mass spectra were viewed 
both in MassLynx, (Waters Corporation, Manchester, UK) and in mMass, an open source multifunctional mass 
spectrometry  software11,12, upon conversion of the spectra into .txt files. Firstly, peak centroiding was carried out 
in MassLynx. Spectra were then exported in mMass and only the peaks with S/N of 10 or above were labelled. 
Mass lists including known matrix (or matrix cluster, adduct) and trypsin autolysis m/z peaks were generated 
and used in mMass to exclude from the peak labelling irrelevant m/z signals. The spectral mass lists were then 
searched against the Excel tables. Peak assignment was automatically performed using an Excel macro. A peptide 
match was confirmed in mMass within a mass accuracy of 30 ppm. These signals were then ultimately checked 
in MassLynx and confirmed if within a relative error of 15 ppm.
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MS/MS spectra opened in MassLynx were converted in .txt files and viewed in mMass for smoothing and peak 
labelling prior to launching an automatic Mascot MS/MS search from within the software. As search parameters, 
Chordata or mammalia were chosen as taxonomy when in the suspected presence of chicken (chordata), bovine 
and porcine (mammalia) blood respectively. Mass Tolerance was set at 40 ppm for the precursor ion and as 
60 ppm for the ion fragments.  MH+ and monoisotopic ions were selected and 2 missed cleavages and variable 
methionine oxidation were included in the y, b, a and c ion fragment search.
Methods. Extraction, and proteolytic digestion and purification of blind and reference samples. The trypsin 
Gold and RapiGest solution was prepared just before proteolysis. RapiGest (0.1% v/v in 50 mM ammonium bi-
carbonate solution) was added to Trypsin Gold to reconstitute it in a 150 µg/mL solution. Stains and marks were 
extracted and digested by adapting a previously published method by Patel et al.9. Each blind stain/fingermark 
sample was swabbed with 70% ACN:  H2O. The swab head was removed using scissors and transferred into an 
eppendorf where 1 mL of 70% ACN:  H2O solution was added prior to sonication for 10 min. Ten µL of the 1 mL 
extract were added to 40 µL of 40 mM Ammonium Bicarbonate and to 9 µL of trypsin solution at a concentra-
tion of 20 µg/mL and RapiGest (0.1% v/v). The sample was then incubated for 1 h at 37 °C and the proteolytic 
digestion was stopped with the addition of 2 µL of 5% TFA. Digests were stored at − 80 °C until analysis. Prior 
to analysis samples were pre-purified using C18 ZipTips according to the standard protocol and peptides were 
eluted in 5 µL of 50:50 ACN: 0.1% TFA.
Commercially available intravenous animal blood samples from bovine, porcine and chicken (both with and 
without EDTA) were also subjected to in solution proteolytic digestion in order to obtain reference spectra. Five 
microliters of each blood reference sample was diluted 1 in 200 with  H2O and 10 µL of the diluted blood were 
subjected to enzymatic digestion and purification protocols as described for the blind samples.
Matrix and application. Ten mg/mL α-CHCA in 70:30 ACN: 0.5% TFAaq was deposited by spotting 0.5 µL on 
top of the sample for profiling experiments.
Results and discussion
Blind samples consisting of stains and fingermarks were prepared on aluminium slides in the following matrices: 
human semen, saliva and sweat, matrices unrelated to any biofluid (egg yolk, beetroot, lotions, steak sauce and 
ketchup), human blood, animal blood (porcine (pig and wild boar), bovine and avian (chicken)). All of the 
samples were supplied either as unenhanced or enhanced using three blood enhancement techniques (BET) such 
namely Acid Black 1 (AB-1), Acid Yellow 7 (AY-7) and Leucocrystal Violet (LCV). To the authors’ knowledge this 
is the first study of its kind to address validation of a technique for blood detection and provenance determination 
using blind samples, and of considerable diversity, in combination with the prior application of BET.
Within the selected pool of animal species and biofluids, the data acquired from the blind samples can 
theoretically enable five levels of identification (ID levels I–V) namely (I) confirmation of presence/absence of 
blood; (II) determination of blood provenance (human or animal); (III) determination of blood provenance at 
animal species level; (IV) determination of the presence of biofluid other than blood; ((V) determination of the 
type of biofluid. This study focussed on the first three levels of identification. However, during the study, semen 
biomarkers were also identified thus tapping into ID levels IV–V.
Development of the interpretative strategy. The main interpretative hypothesis was that by target-
ing proteins specific to human or animal blood, it was possible to both detect and source attribute this biofluid. 
MALDI MS, MALDI MS/MS and LC MS/MS were employed for a selected sample subset to both determine 
and confirm the identity of relevant ion signals. Once the analysts had made an identity claim on the sample 
analysed, its true identity was disclosed to assess effectiveness of the interpretative strategy. Figure 1 summa-
rises the type of samples investigated and the general strategic approach. Retrospective analyses of samples that 
had been incorrectly classified allowed for strategy refinement in an iterative manner. This refinement included 
the re-definition of the S/N threshold and the mass accuracy for peak picking (the latter based in part on the 
instrumental calibration and in part on average instrumental performance) which were eventually set at 10 
and 15 ppm respectively. For animal blood attribution, sample preparation was modified with respect to the 
initial experimental protocol by introducing a pre-purification step using C18 ZipTips after proteolysis. Sample 
purification led to a better S/N ratio and more peptide ion populated spectra when in the presence of animal 
blood. Initially, for animal blood attribution, in addition to identifying the frequency of the putative presence of 
proteotypic peptides across the animal species investigated (within the subset of blood proteins taken in consid-
eration), the frequency of putatively detected shared peptides per species was used as an additional interpretative 
criterion. However, this criterion confounded data interpretation leading to the wrong claim and was therefore 
discounted.
ID level I: detection of blood. Initially, detection of blood was based on the detection of the two most 
abundant haemoglobin (HB) peptides at m/z 1274.725 (βHB LLVVYPWTQR) and at m/z 1529.734 (αHB 
VGGHAAEYGAEALER). Within the system under investigation, these peptides are shared between human, 
porcine and bovine species only; therefore, if chicken blood was present, this would go undetected. However, 
an unexpected chicken blood marker was later detected (see “ID level III: influence of blood collection method 
and animal blood species attribution” section), thus permitting ID Level I when in presence of any of the blood 
sources investigated.
5Vol.:(0123456789)
Scientific Reports |        (2020) 10:17087  | https://doi.org/10.1038/s41598-020-74253-z
www.nature.com/scientificreports/
ID level II: discrimination between human and animal blood. The distinction between human 
and animal blood was not straightforward. The two most abundant peptide markers at m/z 1274.725 and m/z 
1529.734 were used again as positive blood markers as a starting point.
The βHB peptide at m/z 1274.725, despite being clearly at its highest intensity in human blood mass spectra, 
is also shared with porcine and bovine blood. Similarly, the αHB at m/z 1529.734 is present in both human 
and bovine blood. Therefore, the simultaneous presence of both peptides could only mean that the sample did 
contain blood and could be of either human or bovine origin (in this study, where the blood was known to have 
single provenance).
To determine whether the blood was of human versus animal (bovine) origin, identification initially relied on 
the detection of human blood protein derived proteotypic peptides such as that at m/z 932.520 (βHB peptide), 
Figure 1.  Blind samples investigated and general experimental and analytical approach. (A) shows the 
subdivision of the blind samples and their investigation in a stepwise approach within a refining strategy validated 
through a final subset of 13 blind samples. Analyses were performed by MALDI MS with some selected samples 
submitted to MALDI MS/MS and/or LC MS/MS for protein identification/identity confirmation. (B) shows the 
five levels of identification theoretically permitted by the data. Of these levels, this study pursued the first three 
(continuous line) and generated some knowledge towards levels 4 and 5 (dotted line).
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m/z 1087.553 (EPB42, UniProtKB–P16452) and 1378.694 (Hpt UniProtKB–P00738). However, these additional 
ion signals were only occasionally detected and often of a low intensity and resolution or borderline acceptable 
mass accuracy. Therefore, eventually, an ID Level II claim was made and human blood was identified if both of 
the two signals at m/z 1274.725 and 1529.734 were present, with the caveat that there might have been instances 
of false (human blood) positives considering that these peptides are found in bovine HB amino acid sequence too. 
In practice, it has been verified that in all the samples examined, both of the above signals are present together 
only in human blood. Therefore, this ID Level II criterion was brought forward for interpreting the final set of 
13 pre-validation samples (see “Analysis of the final validation set of blind samples” section). The reliance on 
the simultaneous detection of the signals at m/z 1274.725 and m/z 1529.734 for human blood resulted in a 1/40 
false positive for human blood (Sample 1 S was bovine blood) (Table 1).
Table 1.  Initial MALDI MS proteomic analysis of 40 blind samples randomly selected and in order of analysis. 
S (stain), F (fingermark). BET indicates “blood enhancement technique” and the corresponding column shows 
“none” for none applied or reports the name of the technique with the enhancement result; “−” indicates no 




reaction I ID level (blood?)
II ID level (if blood, 
human/animal)
III ID level (animal 
species?) True identity Correct claim?
1 S None Yes Human N/A Bovine No
2 S None Yes Human N/A Human Yes
3 S None Yes Human N/A Human Yes
5 S AB-1 + Yes Animal Bovine Bovine Yes
6 S None Yes Human N/A Human Yes
7 S None Yes Inconclusive Inconclusive Porcine No
12 S None No N/A N/A Sweat Yes
13 S LCV+ No N/A N/A Porcine No
14 S AB-1 + No N/A N/A Human No
16 S None Yes Human N/A Human Yes
17 S None Yes Human N/A Human Yes
18 S None Yes Animal Porcine Wild boar Yes
26 S LCV− No N/A N/A Saliva Yes
27 S None No N/A N/A Semen Yes
28 S None No N/A N/A Bovine No
29 S AY-7 + No N/A N/A Chicken No
30 S AB-1 + No N/A N/A Egg yolk Yes
31 S LCV+ Yes Human N/A Human Yes
34 S LCV+ Yes Human N/A Human + EDTA Yes
35 S None No N/A N/A Chicken No
36 S None No N/A N/A Ketchup Yes
37 S None Yes Human N/A Human Yes
40 S None No N/A N/A Sweat Yes
41 S AB-1 + No N/A N/A Ketchup Yes
49 S AB-1 + No N/A N/A Saliva Yes
53 S None Yes Human N/A Human + EDTA Yes
56 S None No N/A N/A Porcine No
57 S None No N/A N/A Paint Yes
59 S None Yes Human N/A Human Yes
60 S AY-7 + No N/A N/A Saliva Yes
61 S None Yes Human N/A Human Yes
63 S LCV− faint No N/A N/A Chicken No
78 S None No N/A N/A Lotion gold bond Yes
79 S None No N/A N/A Blank Yes
122 F AY-7 + Yes Human N/A Human Yes
141 F AB+ (spotty) No N/A N/A Ketchup Yes
160 F AY-7 − No N/A N/A Saliva Yes
162 F AB-1 + Yes Human N/A Human Yes
165 F AY-7 + No N/A N/A Egg white Yes
175 F LCV− No N/A N/A Egg white Yes
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Table 1 also shows that out of 15 human samples, only sample 14 S (in which the signals at nominal m/z 1275 
and 1530 were absent) resulted in a false negative for human blood. Other m/z proteotypic peptides for human 
blood previously identified were also absent. A new protein digest was prepared from sample 14 S extract yield-
ing the same results.
As the original sample was no longer available and given that this is the only false negative for human blood, 
it is speculated that sample mislabelling occurred (a different analyst prepared the sample at the time). As 
Table 1 shows, the method also works for human blood mixed with EDTA (chemical agent preventing blood 
coagulation). Furthermore, correct human blood identifications were made compatibly with the prior application 
of blood enhancement techniques (LCV, AY-7 and AB-1). These tests correctly indicated the presence of blood but 
it is important to bear in mind that they cannot discriminate between blood of human and animal provenance.
When in the presence of matrices unrelated to blood or to any biofluid (such as ketchup, egg yolk, paint 
etc.), the samples were correctly classified, using the MALDI MS based strategy, as “non-blood” (9/9 correct 
classification). Interestingly, contrary to MALDI MS results, the presumptive test incorrectly indicated blood 
presence in a few instances (e.g. sample 41—ketchup; sample 30—egg yolk; sample 165—egg white).
ID level III: influence of blood collection method and animal blood species attribution. The adoption of HB and 
other animal blood specific protein markers (through proteotypic peptides) largely failed to discriminate the 
provenance of animal blood. Table 1 shows that for 7/9 animal blood samples, the MALDI MS based strategy 
yielded an incorrect “non-blood” claim with 3/3 false negatives for chicken blood, 3/4 false negative for porcine 
blood and 2/3 false negatives for bovine blood. In order to understand why animal blood classification was 
unsuccessful, blood reference samples for bovine, porcine and chicken were investigated to determine the pep-
tide targets to search for within the animal blood blind sample spectra. It was quickly determined that, for all 
the species, the commercially available blood reference spectra were very different from the corresponding blind 
animal sample spectra. Figure 2 shows an example comparing the MALDI MS spectra from commercially avail-
able chicken blood and from the blind chicken blood sample 10. As it can be seen, HB ion signals at m/z 999.487, 
1036.561, 1164.648, 1288.736, 1302.645, 2226.129 (βHB, UniProtKB–P02112) and at m/z 1645.776, 1847.900, 
2121.142 and 2249.224 (αHB, UniProtKB–P01994) could only be putatively observed for the reference blood. 
At this stage it was disclosed that, while human blood was collected through phlebotomy, the animal blood col-
lected for the blind study was obtained from a butcher in the US by harvesting any volume of blood that had 
collected in the chest cavity which then was pooled with a large volume syringe (one per animal).
The collection of chicken blood was reported to be the most challenging due to significantly less blood 
present and the quick dilution with water during the cleaning/processing of the animal. This could explain 
the lack of detection of HB signals in the blind sample 10. At this stage, only the peptides at m/z 1321.746, 
1537.754, 1580.817, 1662.858, could be putatively assigned in the blind sample 10 spectrum and were attributed 
to apolipoprotein 1 (ApoA1, UniProtKB–P08250). Of these 4 assignments, only the ApoA1 signal at m/z 1580.817 
(1–22, IRDMVDVYLETVK) was found in both sample 10 and the blood reference spectrum.
Notably the most intense ion signals at m/z 1391.746, and 1749.798 and 1778.923 could not be assigned to any 
of the most abundant/blood specific proteins under investigation nor could a Mascot search identify these peaks.
The same type of spectral comparison is reported in Supplementary Fig. S1 for bovine (A) and porcine (B) 
blood. The blind samples exhibited a much greater complexity in terms of ion population.
Furthermore, porcine and bovine HB signals, clearly present in the reference spectra (from commercially 
available blood) could not be detected in the corresponding blind sample spectra. The reference blood had been 
collected for all animals through an incision of the jugular vein with the blood subsequently stored in EDTA. 
This would explain why HB peptide signals are the most intense in the reference blood spectra.
As blind samples exhibited a different mass spectral profile from the corresponding intravenous blood, it was 
hypothesised that a different method of collecting blood, closer to how the blood samples were prepared, could 
be more suitable than intravenous blood to act as a reference blood. Consequently, it was investigated whether 
the blood collected from packaged meat and blood residues originating from butcher prepared meat had mass 
spectral profiles superimposable with those from the blind samples or the reference spectra. This investigation 
was crucial to the ability to discriminate animal species and it became even more interesting because, if the 
spectra were different, then the difference would be strictly correlated to the way in which blood was harvested.
For blood detection studies, this circumstance would imply that it is incorrect to just target the most 
abundant proteins that one would normally expect to find in blood. If different blood protein compositions 
are possible, these different “systems” need to be understood. Wounded animals perhaps resemble the closer 
scenario to intravenous blood; blood traces from touching the meat prepared directly from a butcher is possibly 
a more common scenario at crime scenes and, with the widespread purchasing and handling of packaged meat, 
bloodstains or blood fingerprints could also derive from this form of animal blood contamination.
Determination of a chicken blood biomarker. As mentioned above, for chicken blood, the signal at m/z 
1749.798 detected in the blind sample 10 was one of the most intense unassigned signals. This ion signal was also 
present in packaged and butcher freshly prepared meat but not in the intravenous blood. Initially, a MALDI MS/
MS analysis was performed on this ion at nominal m/z 1750 in the freshly prepared meat, the packaged meat and 
blind samples. All but the blind sample yielded the identification of glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) (UniProtKB P00356), through the peptide LVSWYDNEFGYSNR (theoretical m/z 1749.787), with a 
Mascot score of 117 and 62 respectively which are of statistical significance. The subsequent use of LC MS/MS 
enabled confirmation of GAPDH within the blind sample 35 S (as sample 10 S was no longer available) (Fig. 3), 
through the doubly charged ion at m/z 835.397 eluting at 15.06 min, with a Mascot score of 92.
Table 2 summarises the MS/MS GAPDH identifications from the three samples analysed.
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Figure 2.  MALDI MS spectra of commercially available chicken blood (top panel) and of blind sample 10 
(chicken bloodstain, bottom panel) showing overall different spectral profiles.
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Following the peptide identification at nominal m/z 1750, other GAPDH signals were searched for in the 
spectra of both sample 35 S and 10 S (chicken blood) and the additional GAPDH signals at a nominal m/z of 795, 
805, 1033, 1359 and 1646 were assigned with a mass accuracy ranging between 13.2 and 3.6 ppm.
Figure 3.  LC MS/MS spectrum of the doubly charged ion at m/z 875.397 in sample 35 S. This spectrum yielded 
the identification of chicken GAPDH with a Mascot score of 92. The fragment ions not annotated on the peptide 
sequence in the figure indicate that they have not been detected.
Table 2.  Summary of selected sample submitted to MS/MS analysis and yielding identification/confirmation 
identity of a chicken blood biomarker (GAPDH).
Ion signal m/z (Th) Analysis Mascot Score
ID protein and UniProt 
accession number Sequence Ion fragments detected
Chicken packaged meat
1749.855 MALDI MS/MS 62 GAPDH–P00356 LVSWYDNEFGYSNR y1–y12; b8–b9
Chicken butcher freshly prepared meat
1749.793 MALDI MS/MS 117 GAPDH—P00356 LVSWYDNEFGYSNR y1–y12; b6–b8
Chicken sample 35 S
875.397 LC MS/MS 92 GAPDH—P00356 LVSWYDNEFGYSNR y1, y3–13; b2–b6
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Determination of bovine and porcine blood biomarkers. Glyceraldehyde-3 phosphate-deydrogenase (GAPDH) 
The signal at m/z 1749.787 was absent in bovine and porcine blind blood samples. However, a signal at m/z 
1763.802 was consistently present in the bovine and porcine blind sample spectra but absent in the correspond-
ing intravenous blood. MALDI MS/MS analysis and Mascot searches were performed on this ion at nominal 
m/z 1764 for porcine sample 7 S and packaged meat, yielding the identification of porcine GAPDH (UniProtKB–
P00355) with a statistically significant Mascot score of 69 and 122 respectively, through the peptide of sequence 
LISWYDNEFGYSNR. This sequence differs from that found in the chicken GAPDH protein by an isoleucine 
replacing a valine (mass difference of 14 units) in the second position of the peptide. The presence of GAPDH in 
sample 7 S was additionally confirmed with a Mascot score of 93, through LC MS/MS of the doubly charged ion 
at m/z 882.405 (Fig. 4) eluting at 15.65 min.
Bovine GAPDH (UniProtKB-P10096) was confirmed through LC MS/MS of blind bovine sample 38 S with 
a MASCOT score of 100 by fragmenting the doubly charged ion at m/z 882.405.
As for the chicken blood, the blood spectral profiles for the blind bovine and porcine samples (38 S and 7 S 
respectively) reported in Fig. S1 were re-investigated. With reference to these spectra, GAPDH was putatively 
detected via multiple peptides in both the bovine and porcine blind samples but not in the corresponding 
intravenous blood. However, the only ion signal consistently present across all of the bovine and porcine samples 
analysed to that point was that at nominal m/z 1764.
GAPDH is normally used as a housekeeping gene or ‘internal control in experiments’ due to its relatively 
constant expression at high levels in skeletal muscle under changing  conditions13 (in chicken, GAPDH is reported 
to have the highest expression in skeletal muscle). The expression of this protein explains why these signals were 
only detected in the blind samples and not in the intravenous blood.
Therefore, ultimately, the hypothesis that blood has a different protein profile, depending on how “blood was 
generated/collected” has been verified, at least with reference to the way the blood was collected for the blind 
animal sample preparation and the animal intravenous blood.
Figure 4.  Annotated LC MS/MS spectrum of m/z 882.405 from sample 7 S confirming the presence of porcine 
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Table 3 reports and summarises the selected samples submitted to MS/MS and yielding GAPDH biomarker 
identification of porcine and bovine blood.
The identification of the signals at nominal m/z 1750 and 1764 permitted a data interpretation strategy 
refinement; when blood presence is confirmed and human blood is excluded, the presence of the ion at nominal 
m/z 1750 indicates presence of chicken blood via the protein GAPDH. Should the ion at nominal m/z 1750 be 
absent, the GADPH peptide at m/z 1763.802 confirms the presence of animal blood but cannot distinguish 
between porcine and bovine blood.
Myoglobin- Further investigation into the spectra of the blind bovine blood samples that had been incorrectly 
classified (Table 1) allowed for the putative identification of other bovine blood markers. Bovine blood exhibited 
the presence of the signals at m/z 1669.837 and m/z 1592.822 which were putatively attributed to myoglobin 
(UniProtKB–P02192), initially on the basis of their m/z and their mass accuracy (< 15 ppm). Myoglobin peptide 
at nominal m/z 1593 was confirmed (VEADVAGHGQEVLIR) in the blind bovine blood sample 38 S through 
LC MS/MS by fragmenting the doubly charged ion signal at m/z 796.924 eluting at 11.18 min, with a MASCOT 
score of 93 (Fig. 5).
This identification was also confirmed in sample 1 S (previously incorrectly classified) via MALDI MS/MS of 
the ion at m/z 1592.829, with a statistically significant Mascot score of 58 (Table 3). It was not possible however, 
to assign definitively the peptide at m/z 1669.837 by either MALDI MS/MS or LC MS/MS analysis due to an 
insufficient number of ion fragments. However, this signal was still used as a putative identification for bovine 
myoglobin. Although the signal at nominal m/z 1593 appears in all of the bovine samples, that at nominal 
m/z 1670 does not. The former ion signal shares the same sequence in porcine myoglobin though it is never 
detected in the porcine blind samples. Another signal at nominal m/z 649 was identified as porcine myoglobin 
(UniProtKB–P02189) on the basis of the m/z and mass accuracy (< 10 ppm). This signal was present in all but 
one porcine blind samples analysed.
Therefore: (i) the presence of bovine blood was claimed if markers at nominal m/z 1764, 1593 and/or 1670 
were present (within the set mass accuracy); (ii) the presence of porcine blood was claimed if the signal at a 
nominal m/z 1764 was present and signals at nominal m/z 1593 and/or 1670 were absent. Confidence in making 
this claim was increased if the signal at nominal m/z 649 was also present.
Following the identification of myoglobin through the peptide at nominal m/z 1593, this protein was also 
retrospectively identified in bovine sample 38 S (but not in the corresponding intravenous blood) though multiple 
peptides with a mass accuracy ranging between − 11.2 and 2.5 ppm.
Supplementary Table S1 summarises the identifications of haemoglobin, GAPDH and myoglobin biomarkers 
in blind samples 7 S (porcine blood) and sample 38 S (bovine blood) versus the corresponding intravenous 
reference blood showing marked differences in the presence of these proteins. The presence and nature of 
GAPDH, and myoglobin in the blind samples aligns with the location from which blood was harvested.
Within the "system" investigated, altogether these results indicate the opportunity of performing further 
source attribution (ID Level III) by differentiating chicken, bovine and porcine blood through a refined strategy.
Identification of semen: a glimpse into ID levels IV and V. A further sample had been incorrectly 
classified as human blood. This was one of the earliest blind samples analysed and the claim was incorrectly 
based on the presence of only one signal, the αHB peptide at m/z 1529.734 (mass accuracy 0 ppm).
Upon disclosure of the sample identity, the spectrum was inspected more carefully and an intense signal at m/z 
1714.849 was observed. MALDI MS/MS analysis was performed on this precursor ion and a Mascot search was 
launched. Through this search semenogelin-1 (SEM-1 UniProtKB–P04279) was identified through the peptide 
sequence GLRPSEFSQFPHGQK, with a statistically significant score of 99. The MS/MS spectral annotation of 
the ion fragments is shown in Fig. 6.
Table 3.  Summary of selected sample submitted to MS/MS analysis and yielding identification/confirmation 
identity of porcine and bovine blood biomarkers.




7 S 1763.811 MALDI MS/MS 69 GAPDH LISWYDNEFGYSNR y1–y9; b3, b8
7 S 882.405 LC MS/MS 93 GAPDH LISWYDNEFGYSNR y1–y12; b2–11; a2, a4–a5, a8, a11
Packaged meat 1763.786 MALDI MS/MS 122 GAPDH LISWYDNEFGYSNR y1–y12; b2–b6, b8–b11; a2
Bovine blood
38 S 882.405 LC MS/MS 100 GAPDH LISWYDNEFGYSNR y2–y12; b2–b3, b5, b8; a2, a4
38 S 796.921 LC MS/MS 93 Myoglobin VEADVAGHGQEV-LIR
y1, y7–13; b2, b4–b5, 
b11–b12, b14; a2
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SEM-1 is produced in the seminal  vesicles14 and it is abundant in semen. Semenogelin was also identi-
fied by Iliano et al. by LC MS/MS4 and it is the target for a semen confirmatory test employing a lateral flow 
immunochromatographic test strip containing colloidal gold-conjugated anti-human semenogelic monoclonal 
 antibodies15 (Rapid Stain Identification (RSID)).
Additional ion signals were putatively assigned to this protein at m/z 1444.764, 1501.744 and 1801.918 with 
a mass accuracy of 6.6, 0.5 and 13.1 ppm respectively (Supplementary Fig. S2).
Encouraged by these results, a thorough search of other semen specific proteins was performed on the 
basis of the literature available and Semenogelin-2 (SEM-2, UniProtKB–P04279) was also putatively detected 
(Supplementary Fig. S2) (m/z 1883.936, mass accuracy 0.3 ppm; m/z 1444.764, shared with SEM-1, mass accuracy 
6.6 ppm; m/z 1554.779, mass accuracy 8.6 ppm). SEM-2 has additionally been reported as a protein biomarker 
for semen detection through mass spectrometric based techniques and also using  miRNA16–18. Of these ion 
signals, those at nominal m/z 1445 (SEM-1/SEM-2) and 1555 (SEM-2), were consistently found in the semen 
samples analysed; therefore these markers were also implemented for the rapid identification of remaining 
semen samples in the study. The putative presence of the signals at m/z 1529.734 (αHB) and 1314.682 (βHB) 
does not allow for the exclusion of the (weak) co-presence of blood within semen. This instance was important 
for the consideration that, within real crime scenes, it is possible that blood and semen may both be present in 
a stain; therefore confirmatory MS/MS analyses would be needed given that the finding would be of significant 
relevance to an investigation.
Upon retrieval of the SEM-1 marker at nominal m/z 1715, subsequently semen samples (blind to the analyst) 
were not only dismissed as blood but also correctly identified as semen (Table 4).
Figure 5.  Annotated LC MS/MS spectrum of doubly charged ion at m/z 796.924 from sample 38 S confirming 
the presence of porcine GAPDH. Missing annotation on the peptide sequence denotes lack of detection of that 
particular b/y ion fragment.
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Figure 6.  MS/MS spectrum and ion fragment annotation of SEM-1 detected in sample 32. b and y ion are 
annotated and also shown on the peptide sequence; a and c fragment ions are only annotated in the spectrum. 
Missing annotation on the peptide sequence denotes lack of detection of that particular b/y ion fragment.
Table 4.  Analysis and identification of semen blind samples. S (stain), F (fingermark). BET indicates “blood 
enhancement technique” and the corresponding column shows “none” for none applied or reports the name of 
the technique with the enhancement result; “−” indicates no enhancement whereas “+” indicates enhancement. 
AB-1 (Acid Black 1); LCV (Leucocrystal Violet).
Sample no. BET I ID Level (Blood?)
II ID level (if blood, 
human/animal
III ID level (which 
animal species?) True identity Correct claim?
32 S LCV − Yes Human N/A Semen No
Following retrieval of semenogelin-1 marker at nominal m/z 1715
27 S None No N/A N/A Semen Yes
58 S AB-1 + No N/A N/A Semen Yes
132 F LCV (− 1 area/residue) No N/A N/A Semen Yes
158 F AB-1 + No N/A N/A Semen Yes
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Semen was correctly classified even when the sample was pre-enhanced with Acid Black 1 (AB-1) or Leuco-
crystal violet (LCV). Crucially, where AB-1 gave a positive reaction (samples 58 S and 158 F), MALDI analyses 
correctly refuted the results of the presumptive test identifying semen instead.
Figure 7 reports the interpretative strategy that was finalised to identify blood samples (from human and 
animal species) and semen. This strategy was used for revisiting some of the samples incorrectly identified and 
11 additional blind samples as described in the following section.
Blind sample cohort summary of results after identification of animal blood markers and par‑
tial re‑visitation of some samples. Following the identification of bovine/porcine and chicken blood 
markers, some of the samples incorrectly classified were either re-acquired or re-prepared (extraction, proteo-
lytic digestion and purification). Also, 11 new blind samples were analysed encompassing a mixture of human 
and animal blood, biofluids and non-biofluids.
Table 6 reports the identification results for a total of 56 samples including the 44 reported in Tables 1 and 4 
(with some of the samples being re-visited as explained above) and the additional 11 samples. As it can be seen 
from Table 3, a 0% false positive rate for human blood was obtained.
One more false negative for human blood occurred for sample 170 F (total 2/13 false negatives), the spectrum 
of which exhibited none of the ion signals characteristic of blood. A case of mislabelling is still plausible. However, 
upon disclosure of sample identity, it was revealed that it was a human blood “trace”, meaning that it originated 
from the last mark of a depletion series deposited from a nearly dry and exhausted blood source on the fingertip.
The deposited mark was barely visible (as visible as a latent mark) and it is possible that the blood transfer 
was so minimal that the instrumental sensitivity was insufficient.
When blind non biofluid-related samples were analysed (beetroot juice, paint, ketchup), again a 0% false 
positive rate for blood was achieved (0/12 samples). When in the presence of biofluids, semen was correctly 
identified every time (100% correct identification rate) and a 0% false positive rate for blood was achieved 
overall (0/13 samples).
When in the presence of animal blood, whilst prior to discovery of the GAPDH and myoglobin marker, 7/9 
samples were incorrectly classified as “non blood”, after deployment of the refined strategy (Fig. 7) the false nega-
tive rate decreased from 77.7% (7/9 samples) to 6.7% (1/15 samples). In particular, before strategy refinement a 
Figure 7.  Refined blind sample spectra data interpretation strategy. This strategy enables the determination of 
the ID Levels I–III of animal provenance down to species as well as the determination of the presence of semen 
(ID Level IV and V). The m/z values are nominal. Their presence is verified with a mass accuracy < 15 ppm.
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false negative rate of 100% (3/3 samples), 75% (3/4 samples) and 66.7% (2/3 samples) was yielded for chicken, 
porcine and bovine respectively. After strategy refinement, the false negative rate decreased to 0% (0/5 samples), 
16.7% (1/6 samples) and 0% (0/4 samples) for chicken, porcine and bovine respectively. The additional new 
11 samples analysed after strategy refinement shown in Table 5 (in bold) were all correctly classified, whether 
enhanced or not.
Analysis of the final validation set of blind samples. Confirmed markers for human blood, animal 
blood and semen were taken forward in a “final validation” of the method applied to a representative set of 
additional 13 enhanced and non-enhanced blind samples including a range of stains and marks in blood, semen, 
other biofluids and non-biofluid related matrices.
Out of these 13 samples, 12 were correctly identified (Table 6). Once again, there was an instance where a 
presumptive test incorrectly indicated blood when the sample was instead correctly identified by MALDI MSP 
as semen (sample 176 F).
Sample 138 F was correctly classified as animal blood; the myoglobin peptide marker at nominal m/z 1593 
was detected in this sample but the marker at nominal m/z 1764 was not. As a result, the claim of bovine blood 
was not made. From this, it can be surmised that, in bovine blood, the GAPDH marker at nominal m/z 1764 
does not need to be present in addition to the myoglobin signal at m/z 1593, in order to correctly identify this 
animal species as the source of blood.
From a forensic perspective, it is important to highlight that these samples were, at the point of the proteolytic 
digestion and analysis, 3 years old. Therefore the successful application of the strategy devised to these samples 
opens up the avenue for investigation of cold cases.
Conclusions
This study aimed at providing validation data to support the previously reported application of MALDI MS and 
proteomics-based methods for the detection and provenance of blood. The rationale behind the development, 
improvement and validation of such methods are the reduced analysis time, the easier data acquisition and 
the user friendly data interpretation. A range of validation samples were prepared blind to the analyst team 
(including the design of sample collection). Samples included fingermarks and stains prepared with a biofluid 
(human semen, saliva or sweat), human blood, animal blood (domestic pig, wild boar, chicken and bovine) or 
biofluid—unrelated matrices. A sample subset was pre-enhanced with either Acid Black 1, Acid Yellow 7 or 
Leucocrystal Violet. The work presented in this study focuses on an adapted protocol for sample extraction and 
in solution digestion. However, the approach can easily be transferred to in situ proteomics for both profiling 
(for pure detection of blood and its provenance) and imaging purposes (when the information of blood presence 
and provenance is visualised directly on the ridge pattern), as our previous studies have shown.
The present study demonstrates that the overall analytical approach developed enables, regardless of the prior 
blood enhancement technique used (within the system under investigation): (a) determination or exclusion of 
blood presence; (b) discrimination between human blood and animal blood; (c) determination of animal blood 
at a species level; (d) determination of presence (or co-presence) of semen. Notably, in some cases the method 
was able to correctly refute the positive indication on the presence of blood given by the presumptive test.
Given that semen markers were also found, the MALDI based method is on track to become a multiplexed 
approach for the screening of biofluids.
A key finding was made with respect to the determination of blood provenance at animal species level. 
Contrary to our initial hypothesis, that the most abundant and blood specific proteins could be used as molecular 
targets to prove/disprove the presence of blood and indicate provenance, the relevant markers may instead 
change according to how the blood was “generated” and “collected”. For example, it was rather surprising that 
haemoglobin signals in chicken (blind) samples are not detected and only one is detected (poorly) for bovine 
and porcine blood; conversely, GAPDH a non-blood specific protein is detected in the animal blind samples but 
not within the blood deriving from intravenous collection.
Indeed, the animal mass spectral profiles of the blind samples (collected by a butcher from the blood filling the 
heart cavity of the animal) greatly differed from (i) those obtained for the corresponding intravenous blood, (ii) 
those of the blood residues from packaged meat and (iii) those of the blood originating from butcher prepared 
meat. It was also evident that for the last two types of “blood systems”, a greater instrumental sensitivity is 
desirable due to the extreme blood dilution and the use of preservatives (for packaged meat). For animal species 
determination, the sample preparation design for the next piece of research should consider the most common 
scenarios in which animal blood may be found. Perhaps the most commonly encountered scenario is blood 
contamination from handling packaged and butcher prepared meat and, in a less common scenario, use of 
tools for hunting and dressing game. However, animals being shot or stabbed at a crime scene would produce a 
“blood system” resembling more the composition of intravenous blood. All of these “blood systems” require a 
thorough investigation and multivariate statistical analysis could provide more rapid answers as to the provenance 
markers which can then be subsequently identified. In a subsequent full validation study will use the knowledge 
generated by the pre-validation study presented here, in a much larger project. This will include a higher number 
of surfaces of deposition, donors, blood enhancement techniques and the possibility to lift blood fingermarks 
for imaging purposes when the surface of deposition is not directly amenable to MALDI MS Imaging. An 
exploration of blood composition and biomarkers from additional animal species will provide further versatility 
to the applicability of the method.
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Sample no. BET I ID level (blood?)
II ID level (if blood, 
human/not)
III ID level (which animal 
species?) True identity Revisited? Correct claim?
1 S None Yes Animal Bovine Bovine Yes Yes
2 S None Yes Yes N/A Human blood Yes
3 S None Yes Yes N/A Human blood Yes
5 S AB- + Yes Animal Bovine Bovine Yes
6 S None Yes Human NA Human Yes Yes
7 S None Yes Inconclusive Inconclusive Porcine Yes Yes
12 S None No N/A N/A Sweat Yes
13 S LCV+ No N/A N/A Porcine Yes Yes
14 S* AB-1 + No N/A N/A Human No
16 S None Yes Human N/A Human Yes
17 S None Yes Yes N/A Human blood Yes
18 S None Yes ANIMAL Porcine Wild boar Yes
26 S LCV− No N/A N/A Saliva Yes
27 S None No N/A N/A Semen Yes
28 S None No N/A N/A Bovine Yes Yes
29 S AY-7 + No N/A N/A Chicken Yes Yes
30 S AB-1 + No N/A N/A Egg yolk Yes
31 S LCV+ Yes Human N/A Human Yes
32 S LCV− No N/A N/A Semen Yes Yes
34 S LCV+ Yes Human N/A Human + EDTA Yes
35 S None No N/A N/A Chicken Yes Yes
36 S None No N/A N/A Ketchup Yes
37 S None Yes Human N/A Human Yes
40 F None No N/A N/A Sweat Yes
41 S AB-1  + No N/A N/A Ketchup Yes
49 S AB-1 + No N/A N/A Saliva Yes
53 S None Yes Human N/A Human blood + EDTA Yes
56 S None No N/A N/A Porcine Yes Yes
57 S None No N/A N/A Paint Yes
58 S AB-1 + No N/A N/A Semen Yes
59 S None Yes Human N/A Human Yes
60 S AY-7 + No N/A N/A Saliva Yes
61 S None Yes Human N/A Human Yes
63 S LCV− faint No N/A N/A Chicken Yes Yes
78 S None No N/A N/A Lotion gold bond Yes
79 S None No N/A N/A Blank Yes Yes
122 F AY-7 + Yes Human N/A Human blood Yes
132 F LCV (− 1 area/residue) No N/A N/A Semen Yes
141 F AB-1 + (spotty) No N/A N/A Ketchup Yes
158 F AB-1 + No N/A N/A Semen Yes
160 F AY-7 − No N/A N/A Saliva Yes
162 F AB-1 + Yes Human N/A Human Yes
165 F AY-7 + No NO N/A Egg white Yes
175 F LCV− No N/A N/A Egg white Yes
4 F None Yes Animal Chicken Chicken Yes
24 S None No No N/A Egg Yes
25 S LCV+ Yes ANIMAL BOVINE Bovine Yes
41 S AB-1 + No N/A N/A Ketchup Yes
44 S None Yes ANIMAL PORCINE Wild boar Yes
53 S None Yes HUMAN N/A Human blood + EDTA Yes
72 S None No N/A N/A Steak sauce Yes
76 S AY-7 + No N/A N/A Semen Yes
107 F None Yes Animal Porcine Porcine Yes
144 F None No N/A N/A Blank Yes
170 F** None No N/A N/A Human blood No
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Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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